Zinc oxide nanoparticles (ZnO NPs) are metal oxide nanomaterials, which are important for several applications: antibacterial, anthelmintic, antiprotozoal and antitumoral, among others. These applications are mainly related to the ability to spontaneously produce and induce the production of reactive oxygen species that are important components for the destruction of pathogens and tumor cells. While trying to potentiate ZnO NPs, studies have associated these NPs with silver oxide (AgO) or silver (Ag) NPs. It has already been reported that this combination (Ag-ZnO/AgO NPs) is able to enhance the microbicidal potential. Although possessing much potential for several purposes, it is important to evaluate whether this association also poses the risk of toxicity to cells and experimental models. Therefore, this work aimed to evaluate the toxicity of various Ag-ZnO/AgO NP nanocomposites, in vitro and in vivo. Accordingly, ZnO nanocrystals and nanocomposites with various concentrations of AgO (ZnO:5Ag, ZnO:9Ag or ZnO:11Ag) were used in different cytotoxicity models: Galleria mellonella (G. mellonella), cell lines (VERO and RAW 264.7) and C57BL/6 mice. In the G. mellonella model, four concentrations were used in a single dose, with subsequent evaluation of mortality. In the case of cells, serial concentrations starting at 125 µg/mL were used, with subsequent cytotoxicity assessment. Based on the safe doses obtained in G. mellonella and cell models, the best doses were used in mice, with subsequent evaluations of weight, biochemistry as also renal and liver histopathology. It was observed that the toxicity, although low, of the nanocomposites was dependent upon the concentration of AgO used in association with ZnO NPs, both in vitro and in vivo.
Ticks are significant parasites of dogs in the tropics, where tick-borne pathogens are highly prevalent, especially in areas where tick control measures are frequently neglected. This study investigated the seroprevalence and hematological abnormalities associated with Ehrlichia canis in dogs referred to a veterinary teaching hospital in Central-western Brazil. Out of 264 dogs tested for anti-Ehrlichia canis antibodies by an indirect immunofluorescence assay (IFA), 59.1% (156/264) were positive. Seropositivity was significantly associated to anemia and thrombocytopenia, alone or in combination, and to leukopenia. Conversely, there were no differences in terms of seroprevalence according to sex, breed and age. This study demonstrated that dogs referred to a veterinary teaching hospital in Central-western Brazil are highly exposed to E. canis and that seropositive dogs are more likely to present hematological abnormalities, particularly anemia, thrombocytopenia and leukopenia. To our knowledge, this is the first study on detection of anti-E. canis antibodies by means of IFA among dogs in the state of Goiás. These findings highlighted the need for increasing awareness among dog owners regarding tick control measures in Central-western Brazil, ultimately to reduce the risk of exposure to E. canis and other tick-borne pathogens.
Among the parasitic and infectious diseases affecting cats, those caused by vector-borne pathogens deserve attention due to their ability to cause nonspecific clinical signs and clinicopathological abnormalities. We studied the presence of Cytauxzoon spp., Ehrlichia spp., and Mycoplasma spp. in blood samples from 135 cats referred to the veterinary teaching hospital of the Federal University of Goiás in midwestern Brazil. We also investigated co-infections with Feline Immunodeficiency Virus (FIV) and Feline Leukemia Virus (FeLV) as well as the correlation between Mycoplasma spp. infection and cat variables, including age, sex, breed, and complete blood count abnormalities. Upon PCR testing, 20.7% (28/135) of samples were positive for Mycoplasma spp., 1.5% (2/135) for Cytauxzoon spp., and none for Ehrlichia spp. Co-infections with Mycoplasma spp. and Cytauxzoon spp. were detected in the two cats with the latter infection. Mycoplasma spp. infection was statistically associated with the simultaneous presence of thrombocytopenia and leukocytosis. This study confirms a high frequence of Mycoplasma spp. infection, with both M. haemofelis and ‘Candidatus Mycoplasma haemominutum’ circulating in this cat population. The clinical significance of Mycoplasma spp. infection in cats should be further explored and this infection should eventually be included in the differential diagnosis of thrombocytopenia and leukocytosis in otherwise apparently healthy cats.
The objective of this study was to evaluate the effect of digestible methionine and cystine (Met + Cys) levels on the hematological and serum biochemical parameters of broiler chickens during the initial and growth stages. For this, 1,800 male chicks of the Coob 500 strain were used, with 900 chicks in the initial phase (1 to 21 days old) and 900 chicks in the growth phase (22 to 42 days old), distributed in a completely randomized design of five treatments with six replicates of 30 birds. The treatments consisted of 0.545, 0.616, 0.711, 0.782, and 0.853%; and 0.514, 0.571, 0.647, 0.704, and 0.761% digestible Met + Cys for “1 to 21” and “22 to 42” days of breeding, respectively. Results showed that digestible Met + Cys levels in broiler feed altered some hematological parameters (erythrocyte, hematocrit hemoglobin, total leukocytes, heterophile: lymphocyte) and serum biochemistry (uric acid, PST, total LDL, and TG). The digestible Met + Cys levels in the diet of broilers affected the hematological parameters and serum biochemistry, especially at higher levels. From the inclusion level 0.761 of Met + Cist in the broiler diet, red blood cells, hemoglobin and hematocrit changes begin to appear.
1 February 2011 in Arquivo Brasileiro de Medicina Veterinária e Zootecnia
Brain and serum lipid peroxidation was studied in rats treated with vincristine sulphate and different doses of nandrolone decanoate. Thirty rats were distributed into six groups (n=5). The treatments were applied once a week for two weeks. Sample collection was performed in the third week. Treatments during the first week were: G1 (control) - physiologic solution, G2 - vincristine sulphate (4mg/m²), G3 - physiologic solution, G4 - physiologic solution, G5- vincristine sulphate (4mg/m²), and G6 - vincristine sulphate (4mg/m²). In the second week, they were: G1 (control) - physiologic solution, G2- physiologic solution, G3 - nandrolone decanoate (1.8mg/kg-1), G4 - nandrolone decanoate (10mg/kg-1), G5 - nandrolone decanoate (1.8mg/kg-1), and G6 - nandrolone decanoate (10mg/kg-1). Lipid peroxidation increased with the isolated use of vincristine and nandrolone decanoate, and with vincristine associated to the highest dose of the ester as well. These results suggest that vincristine sulphate and nandrolone decanoate increase free radical production. Therapeutic dose of nandrolone decanoate when associated with vincristine sulphate proved to be beneficial, as it was able to protect the organism from damaging processes involved in free radical production